Genscript Biotech Corporation
1548
주식 순위
#2135
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
주가
$4.26
마지막 동기화: 2026-10-16
시가총액
$9.58B
변동 (1일)
5.38%
변동 (1년)
106.56%
국가
HK
거래 Genscript Biotech Corporation (1548)
카테고리
Healthcare
Genscript Biotech Corporation (1548)의 영업이익률
October 2026 기준 영업이익률 TTM: 14.88%
Genscript Biotech Corporation의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 14.88%입니다. 2023년 말 기준 영업이익률은 3.12%였습니다.
Genscript Biotech Corporation의 영업이익률 기록 (2013 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 14.88% | 853.85% |
| 2024 | 1.56% | -50.00% |
| 2023 | 3.12% | -104.46% |
| 2022 | -70.02% | -9.52% |
| 2021 | -77.39% | 47.89% |
| 2020 | -52.33% | 8.91% |
| 2019 | -48.05% | -2,274.21% |
| 2018 | 2.21% | -91.48% |
| 2017 | 25.93% | 19.33% |
| 2016 | 21.73% | 72.87% |
| 2015 | 12.57% | 23.72% |
| 2014 | 10.16% | -28.90% |
| 2013 | 14.29% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -97.41% |
US
|
|
| -149.01% | -110.01% |
US
|
|
| 25.57% | -98.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.06% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.